While its COVID-19 vaccine, partnered with US-based Vaxxinity, is set to move to Phase III trials, Aurobindo has acquired an animal health company as well as several ANDAs and OTC assets. The acquisition and a deceleration in US sales caught analysts by surprise.
When Aurobindo Pharma Limited announced its fiscal 2022 first-quarter results, it also notified stock exchanges of an intention to acquire a 51% stake in an Indian animal health company, Cronus Pharma Specialities Pvt. Ltd., for INR4.2bn ($56.5m).
The move into animal health caught analysts by surprise and had the management answering several questions on the business case for the deal during a post-earnings call
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
